Senzime AB

Senzime presents positive data from clinical study of CliniSenz

Pressmeddelande   •   Maj 12, 2014 08:30 CEST

Uppsala, 12 May 2014. Senzime AB (publ) today announced that results from a clinical study of the company's instrument for automatic and continuous monitoring of blood sugar levels - CliniSenzTM - confirm the possibility to identify fluctuations that could not be detected by existing methods. This situation may contribute to increased survival during complicated surgical procedures.The study was conducted at the Uppsala University Hospital and covers some 40 individuals (volunteers and patients). The results indicate high precision and longer measurement periods with CliniSenzTM than with the test methods that are currently used in the hospital.

The study was conducted at the Uppsala University Hospital and covers some 40 individuals (volunteers and patients). The results indicate high precision and longer measurement periods with CliniSenzTM than with the test methods that are currently used in the hospital. 

"Earlier identification of blood glucose level fluctuations is important in intensive care and may also be important in other health care disciplines", says Per-Olof Joachimsson, medical management responsible for Thoracic Surgery and anesthesia, Uppsala University Hospital.

Examples of other potential applications outside the hospital environment include the monitoring of blood glucose levels to demonstrate the effect of food intake and physical exercise for managing diabetes and overweight. 

"The clinical study of CliniSenzTM confirms that the instrument is reliable and user-friendly. The need to continuously monitor blood sugar levels is high, both in health care settings and to increase the awareness of, for example, individuals with diabetes and overweight on how physical activity and food intake can affect their health. Senzime is now looking for a corporate partner to further develop CliniSenzTM and we will also continue the development in-house for niche applications", said Lena Söderström, CEO of Senzime AB.

For further information, please contact:

Lena Söderström, CEO of Senzime AB

Tel: +46-708-16 39 12, e-mail: lena.soderstrom@senzime.com

 

TO THE EDITORS

About Senzime

Senzime develops and sells analytical instruments and related disposable products that enable automated, continuous monitoring of vital substances including glucose (sugar), in biological fluids. Many modern medicines are produced in living cells that are nourished in a glucose solution. In order to ensure maximum productivity in manufacturing, glucose levels should be measured continuously. BioSenzTM is an analytical instrument that performs this task. Senzime's market leading partner, Applikon, has started the global launch of BioSenzTM. Continuous glucose monitoring can also be used by healthcare providers, to improve outcomes of complex surgical procedures and dialysis care. For these purposes, the company develops the instrument CliniSenzTM. The company's share is listed on Aktietorget since 2008.

www.senzime.com


Om Senzime

Senzime utvecklar och säljer analysinstrument med tillhörande förbrukningsmaterial och tillbehör. Utrustningen möjliggör automatiserad och kontinuerlig mätning av viktiga ämnen, bland annat glukos (socker), i biologiska vätskor. Många moderna läkemedel tillverkas av levande celler som hämtar sin näring ur en glukoslösning. Glukosnivån bör mätas kontinuerligt för att säkerställa maximal produktivitet i tillverkningen och BioSenzTM är ett analysinstrument som löser denna uppgift. Instrumentet lanseras globalt av Applikon, Senzimes marknadsledande partner. Kontinuerlig glukosmätning behövs även inom sjukvården för att öka  patientöverlevnaden vid komplicerade kirurgiska ingrepp samt för att förbättra dialysvården. För dessa ändamål utvecklar bolaget instrumentet CliniSenzTM. Bolagets aktie är sedan 2008 noterad på Aktietorget. 

För mer information, se www.senzime.com eller vänligen kontakta:

Lena Söderström, VD

Tel. +46 (0)18 51 56 40

Mobil +46 (0)708 16 39 12


Bifogade filer

PDF-dokument